Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Inclusion Criteria: * Patients with histologically confirmed advanced biliary tract cancer who had experienced progression during first-line gemcitabine and cisplatin * Age 18 years or older * Measurable reference cancer site(s) confirmed with computed tomography (CT) or magnetic resonance imaging (MRI) * Karnofsky performance status (KPS) of at least 70% * Adequate renal function, adequate hepatic function, adequate bone marrow function Exclusion Criteria: * The presence of any severe concomitant disease that could interrupt the planned treatment * Intractable pain * Hypersensitivity to study drugs * Serious cardiovascular disease * If female, pregnancy or breastfeeding